Pete Newham
AstraZeneca (United Kingdom)(GB)AstraZeneca (South Korea)(KR)AstraZeneca (Poland)(PL)
Publications by Year
Research Areas
Bone health and treatments, Bone and Joint Diseases, Energy Efficient Wireless Sensor Networks, Osteoarthritis Treatment and Mechanisms, IoT and Edge/Fog Computing
Most-Cited Works
- → Bone marrow lesions from osteoarthritis knees are characterized by sclerotic bone that is less well mineralized(2009)216 cited
- → Proteolysis‐targeting chimeras in drug development: A safety perspective(2020)207 cited
- → Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors(2004)90 cited
- → 308 ALTERED PERFUSION AND VENOUS HYPERTENSION IS PRESENT IN REGIONS OF BONE AFFECTED BY BMLS IN KNEE OA(2007)8 cited
- → Bromodomain and extraterminal (BET) domain inhibitors induce a loss of intestinal stem cells and villous atrophy(2014)6 cited
- → The value of integrating pre-clinical data to predict nausea and vomiting risk in humans as illustrated by AZD3514, a novel androgen receptor modulator(2016)3 cited
- → 12 BONE MARROW LESIONS FROM OSTEOARTHRITIS KNEES ARE CHARACTERIZED BY SCLEROTIC BONE THAT IS LESS WELL MINERALIZED(2007)1 cited
- → Stem cells, organoids and microphysiological systems coupled to modeling & simulation guide drug discovery and enhance translational safety risk assessment(2017)
- → Modifying the risk-benefit ratio using drug delivery systems(2013)